ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Novartis’ iscalimab results hint at extended survival of transplanted organs
June 11, 2019Novartis has presented first-of-its-kind histology data with iscalimab (CFZ533), suggesting that it may be possible to prolong the durability of transplanted kidneys as well as to potentially improve long-term outcomes for kidney transplant patients.
Pharma Sources Insight January 2025
